Health Condition 1: - Health Condition 2: N37- Urethral disorders in diseases classified elsewhere
Conditions
Interventions
Sponsors
Pfizer PHARMACEUTICALS
Eligibility
Inclusion criteria
Inclusion criteria: WERE CONSECUTIVELY ADMITTED TO THE HOSPITAL BETWEEN 01 APRIL 2020 AND 31 MARCH 2023 HAD SUSPECTED OR DOCUMENTED MDR GRAM NEGATIVE INTRA ABDOMINAL SEPSIS OR UROSEPSIS SEPSIS WAS DIAGNOSED ACCORDING TO THE THIRD INTERNATIONAL CONSENSUS DEFINITION FOR SEPSIS AND SEPTIC SHOCK RECIEVED CEFTAZIDIME AVIBACTUM FOR ATLEAST 48 HOURS AS PER CLINICIAN DISCRETION
Exclusion criteria
Exclusion criteria: DOCUMENTED ACINETOBACTER INFECTION RECIEVED CEFTADIZIME AVIBACTUM LESS THAN 48 HOURS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IN PATIENT MORTALITY CLINICAL OUTCOMES MEASURED ON DAY 3 AND DAY 14 /END OF TREATMENT FROM THE INITIATIONOF CEFTAZIDIME AVIBACTUM TREATMENT.Timepoint: IN PATIENT MORTALITY CLINICAL OUTCOMES MEASURED ON DAY 3 AND DAY 14 /END OF TREATMENT FROM THE INITIATIONOF CEFTAZIDIME AVIBACTUM TREATMENT. | — |
Secondary
| Measure | Time frame |
|---|---|
| 14 DAYS ALL CAUSE MORTALITY MICROBIOLOGICAL OUTCOMES 30 DAYS ALL CAUSE MORTALITY RECURRENCE OF INFECTION SAFETY LENGTH OF HOSPITAL STAY LENGTH OF ICU STAY DY OF CEFTAZIDIME AVIBACTUM INITIATION AVERAGE DOSE AND DURATION CLINICAL OUTCOMES IN PATIENTS INITIATED WITH CEFTAZIDIME AVIBACTUMWITHIN 48 TO 72 HOURS FROM DIAGNOSIS OF INFECTION DISTRIBUTION OF PATHOGENS AND SUSCEPTIBILITY TO CEFTAZIDIME AVIBACTUM IF AVAILABLE GENOTYPING RESULTS IF AVAILABLE CONCOMITANT ANTIBIOTIC MEDICATIONS WITH CEFTAZIDIME AVIBACTUMTimepoint: 14 TO 30 DAYS | — |
Countries
India
Contacts
Public ContactDr Prachee Sathe
Ruby Hall Clinic Grant Medical Foundation, 40 Sasoon Road Pune 411001
Outcome results
None listed